3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Now's a great time to build up a position in Iovance Biotherapeutics (NASDAQ: IOVA) with the aim of holding on to its shares for the next few years. Between the recent launch of its innovative cell therapy, strong progress in building up its network of clinics, and a financial situation that looks well-matched to its substantial needs in the near term, this is a biotech that's as well-positioned as stocks in this very risky category tend to get. Let's take a look at the top three reasons it's worth buying like there's no tomorrow. 1. The infrastructure for growth is coming together quickly Iovance's first cell therapy product, Amtagvi, is a bit complicated to manufacture and administer. Amtagvi treats melanoma using a patient's own tumor infiltrating lymphocyte (TIL) cells. As the name implies, TILs are naturally occurring cells of the immune system that manage to enter the interior of solid tumors, where the tumor's defense mechanisms are less effective, and where the TILs'
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial OfficerGlobeNewswire
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Piper Sandler from $10.00 to $7.50. They now have a "neutral" rating on the stock.MarketBeat
- What's Wrong With Iovance Biotherapeutics Stock? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 11/7/24 - Beat
IOVA
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form 4
- 2/12/25 - Form 3
- IOVA's page on the SEC website